After several failed congressional attempts to meet US President Donald Trump’s request for a so-called ‘right to try’ bill earlier this year, lawmakers have finally succeeded in delivering legislation for him to sign.
The House of Representatives voted, by 250 to 169, to approve a version of the bill that was agreed in the Senate last year.
The bill will give terminally ill patients the right to request that pharma firms provide drug candidates before the US Food and Drug Administration has cleared them for marketing, although firms will not be obliged to do so.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze